Announced Tue, 23 Jun · 18:21 IST
Honasa Consumer acquires 58% stake in Fluence Pharma, enters nutraceuticals
Compliance View source PDF
HONASA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.7%1-day move
₹420.00
prior close
₹429.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.3-2.6-3.9-5.1-0.7+5.8+9.0+11.0+11.3+11.7+11.6+6.7——
Up moveDown movePending
AI summary
Honasa Consumer (Mamaearth parent) is acquiring a 58% majority stake in Fluence Pharma, a science-backed nutraceuticals company, marking its entry into the high-growth nutraceuticals market valued at over INR 16,000 Crore. The deal will be executed through a new subsidiary, Honasa Health. Fluence reported about INR 40 Cr revenue and 20%+ EBITDA margin in FY26, and has a network of 3,000+ dermatologists.
Likely market impact
Strategic diversification into high-growth nutraceuticals; positive for long-term growth and revenue mix expansion.